SK Biopharmaceuticals Co., Ltd. (326030.KS) KSC

Currency In KRW

AD

Valuation

Market Cap9.76T
Enterprise Value9.5T
P/E Ratio15.15
PEG Ratio0.29
Price/Sales Ratio6.81
Price/Book Ratio5.74
Enterprise/Revenue6.43
Enterprise/EBITDA23.45

Fiscal Year

Fiscal YearDecember 31, 2025
Most Recent QuarterJune 30, 2026

Profitability

Profit Margin0.47
Operating Margin0.35
AD

Management Effectiveness

Return On Assets0.28
Return On Equity0.47

Income Statement

Revenue706.74B
Revenue/Share10,998.68
Gross Profit651.67B
EBITDA220.89B
Net Income266.95B
Diluted EPS3,408.75

Balance Sheet

Total Cash381.87B
Total Cash/Share4,876.24
Total Debt48.83B
Total Debt/Equity0.05
Current Ratio2.72
Book Value Per Share13,047.14

Price History

52-Week Change-30.78
52-Week High144,100
52-Week Low67,800
Moving Average 50 Days80,600
Moving Average 200 Days94,368

Statistics

Average Volume126,289
Shares Outstanding78.31M
% Held by InstitutionsN/A

Dividend And Splits

Trailing Annual Dividend Rate0
Trailing Annual Dividend Yield0
Payout Ratio0
Last Split FactorN/A
Last Split DateN/A
AD